Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8557993 | KOWA CO | Crystalline forms of pitavastatin calcium |
Feb, 2024
(1 year, 5 days from now) | |
US7022713 | KOWA CO | Hyperlipemia therapeutic agent |
Feb, 2024
(1 year, 22 days from now) | |
US8557993
(Pediatric) | KOWA CO | Crystalline forms of pitavastatin calcium |
Aug, 2024
(1 year, 6 months from now) | |
US7022713
(Pediatric) | KOWA CO | Hyperlipemia therapeutic agent |
Aug, 2024
(1 year, 6 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | May 16, 2022 |
Pediatric Exclusivity (PED) | Nov 16, 2022 |
Drugs and Companies using PITAVASTATIN CALCIUM ingredient
Market Authorisation Date: 03 August, 2009
Treatment: Adjuncitve therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic